Table 3 Published series about outcome of myocarditis in the paediatric age group.
| Study | Type of myocarditis | No of patients | Clinical data | Viral doc | EMB | Age (years) | IA drugs | Death or Tx | LVF rec/surv |
|---|---|---|---|---|---|---|---|---|---|
| Matitiau9 | AM + AFM | 9 | Yes | Yes | 100% | 0.6* | Yes (n = 4) | 2 | 5/7 |
| Lee5 | AM + AFM | 35 | Yes | Yes | 100% | 3.3* | Yes | 6 | 27/29 |
| Kleinert10 | AM | 9 | No | No | 100% | 2.1† | Yes | 0 | 9/9 |
| Gagliardi7 | AM | 20 | No | No | 100% | 1.9† | Yes | 0 | 10/20 |
| Duncan6 | AFM | 15 | Yes | Yes | 50% | 4.6* | Yes | 8 | 7/7 |
| Stiller19 | AFM | 4 | Yes | Yes | 100% | 4† | No | 1 | 3/4 |
| Calabrese11 | AM | 28 | Yes | Yes | 100% | 4* | NA | 9 | 2/19 |
| Ahdoot12 | AFM | 5 | Yes | No | 80% | 10* | Yes | 1 | 3/4 |
| English21 | AFM + AM | 41 | Yes | Yes | 85% | 2.2* | Yes | 10 | 27/31 |
*Median age; †mean (SD) age.
AFM, acute fulminant myocarditis; AM, acute myocarditis; doc, documentation (titres or cultures); EMB, endomyocardial biopsy evidence of myocarditis; IA, immunoactive (corticosteroids, azathioprine, ciclosporin and intravenous polyclonal immunoglobulin); LVF, left ventricular function; NA, not available; rec, recovery; surv, survivors without heart transplantation; Tx, heart transplantation.